Aug 2026· Immuno· Vol 6, pp. 53· 0 citations· 50 references
TL;DR
ICA-associated phenotypic recovery coincided with partial, non-uniform remodeling of splenic transcriptional programs, and reverse transcription quantitative polymerase chain reaction (RT-qPCR) confirmed dose-associated changes in selected innate immune transcripts.
Abstract
Background: Cyclophosphamide (CTX)-induced immunosuppression involves systemic toxicity, splenic atrophy, and broad transcriptomic disruption. Icariin (ICA) has immunomodulatory activity, but the systems-level features associated with splenic recovery remain incompletely defined. Methods and Results: Male mice were assigned to control, CTX, and CTX plus ICA (20, 40, or 80 mg/kg) groups. Phenotypic measurements were integrated with splenic RNA sequencing, differential expression analysis, targeted gene-set analysis, and weighted gene co-expression network analysis (WGCNA). ICA produced dose-associated improvement in spleen index and body weight trajectory, with the most consistent phenotypic response at 80 mg/kg. Overall transcriptomic separation was supported by permutational multivariate analysis of variance (PERMANOVA) (F = 17.18, R2 = 0.873, p < 0.001). WGCNA identified a recovery-associated turquoise module; Myb was assigned to this module, whereas Gata1 belonged to a distinct royalblue module. Complement and chemokine gene sets provided the strongest targeted enrichment evidence, and reverse transcription quantitative polymerase chain reaction (RT-qPCR) confirmed dose-associated changes in selected innate immune transcripts. Marker-based lineage signatures indicated non-uniform recovery, including persistent depression of the B-cell signature. Conclusion: ICA-associated phenotypic recovery coincided with partial, non-uniform remodeling of splenic transcriptional programs. The Myb- and Gata1-associated findings are hypothesis-generating co-expression signals and do not establish transcription-factor binding or causality.
Hepatic lipid-associated inflammation contributes to metabolic liver disease and cardiometabolic complications. Treatment-based transcriptomic comparisons can obscure inter-individual heterogeneity when animals exposed to the same experimental condition show divergent molecular responses. In the public hyperlipidemic l...
Zihan Li, Fu-Heng Xie, Yu-Qing He et al.· bioRxiv· 0 citations
VAMP8, STX2, MCOLN1, DERL1, and PTP4A2 were identified as candidate molecular markers of HF that reflect alterations in a lysophagy- and vesicular-transport-related program associated with FOLR2+ tissue-resident macrophages.
Qi Cheng, Yan-Li Wang, De-Qiang Wang et al.· Genes· 0 citations
MZT1 is a proliferation-associated marker that integrates clinical risk, transcriptional programs, cellular heterogeneity, and predictive modeling in LUAD, providing a potential framework for biomarker development and risk stratification.
Dahlak Daniel Solomon, Hui-Ru Lin, Yung-Kuo Lee et al.· Cancer Genomics & Proteomics· 0 citations
High FIBP expression is associated with an iron-buffering and antioxidant transcriptional phenotype and adverse survival in AML, but the current data do not demonstrate direct FIBP control of ferroptosis or independent prognostic value of the proposed sensitivity score.
Meng Tang, Jianxin Guo· World Journal of Advanced Re...· 0 citations
A macrophage-centered anoikis-related immune signature in atherosclerosis is defined and HAVCR2 is identified, together with CD36, PLAU, TNF, PYCARD, SERPINA1, BLNK, and CHI3L1, as potential biomarkers and candidate targets for future diagnostic and therapeutic investigation.
Qiang Shen, Zheng-Feng Fan, Jin-Cheng Hou et al.· Frontiers in Immunology· 0 citations
This study provides a systems-level view of immune dysregulation in MG, highlighting enhanced intercellular communication, T-cell dysregulation, and PLEK as a potential molecular marker associated with CD8+ T-cell activation and disease severity, offering insights into MG pathogenesis and therapeutic targets.
Jing-Nan Jin, Zi-Hong Chen, Yi-Ying Zhang et al.· Journal of Neuroimmunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.